ProCE Banner Activity

Phase I/II Trial of Zilovertamab, an Anti-ROR1 Antibody, Plus Ibrutinib in MCL or CLL

Slideset Download
Conference Coverage
In a phase I/II trial, zilovertamab plus ibrutinib was generally well tolerated with robust efficacy compared with historical data for ibrutinib alone in MCL or CLL.

Released: June 15, 2022

Expiration: June 14, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab